Market Overview:
The global human cytomegalovirus envelope glycoprotein B market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cytomegalovirus infections, rising demand for novel therapeutics and vaccines, and growing investments in R&D. However, the high cost of treatment may restrain the growth of this market to some extent. Based on type, the global human cytomegalovirus envelope glycoprotein B market is segmented into CSJ-148, CyMVectin, TRL-345 PPCM and others. Cytomegalovirus vaccine is expected to be one of the fastest-growing segments during the forecast period owing to its increasing adoption for prophylaxis against cytomegaloviral diseases. By application, infectious disease accounted for a major share of this market in 2017; however, oncology is projected to be one of fastest-growing segments during 2018–2030 owing its growing demand for targeted therapies against cancer cells infected with CMV virus.
Product Definition:
Human Cytomegalovirus Envelope Glycoprotein B is a glycoprotein that is found on the envelope of human cytomegalovirus (HCMV). It is important for the virus to bind to host cells and initiate infection.
CSJ-148:
CSJ-148, also known as human cytomegalovirus envelope glycoprotein B is a protein that is manufactured by the Human Cytomegalovirus (HCMV) and it acts as an immunogen to the virus. It's structure consists of a single-chain variable fragment connected to itself via an antibody binding site. The antibody binding site contains both Fab and Fv regions which allow for crosslinking of antibodies with HCMV proteins.
CyMVectin:
CyMVectin and its usage in Human cytomegalovirus envelope glycoprotein B market is expected to register significant growth over the forecast period. Cytomegalovirus is a virus that infects the cells of the immune system, thereby causing disease symptoms such as fever, nausea, vomiting, weakness or aches and pains.
Application Insights:
On the basis of application, the global human cytomegalovirus envelope glycoprotein B market has been segmented into infectious disease, oncology, women¢â‚¬â„¢s health and other applications. The infectious diseases segment dominated the overall market in terms of revenue share in 2017. This is due to a large patient base affected by various types of infections caused by this virus including chickenpox and shingles. In addition, an increase in travel activities across the globe has led to an increased incidence rate for these infections which also contributes towards a significant share for this segment.
The oncology application is expected to witness lucrative growth over the forecast period owing to increasing research initiatives undertaken by private institutions and biopharmaceutical companies with regards to developing new therapeutic drugs specifically designed against CMV-induced mutations that lead towards malignant transformation. For instance; Pfizer Inc.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong research base, advanced healthcare infrastructure, and high adoption rate of novel therapeutics are some factors responsible for its large share. Moreover, increasing incidence of cancer is also expected to boost the demand for cytomegalovirus (CMV) vaccines over the forecast period. For instance, according to data published by American Cancer Society in 2018; more than 1 million new cases were estimated to be diagnosed in 2019 and more than 600 thousand people died due to it that year alone.
Growth Factors:
- Increasing incidence of human cytomegalovirus (HCMV) infection: The global incidence of HCMV is increasing due to various factors such as population growth, increased travel and migration, and changes in sexual behavior. This is expected to drive the demand for HCMV envelope glycoprotein B (gB) vaccine and therapeutics.
- Growing awareness about HCMV infections: There is a growing awareness among people about the risk of HCMV infections and their potential consequences. This is likely to increase the demand for preventive measures such as vaccines and therapeutics against this virus in the coming years.
- Technological advancements in vaccine development: The technological advancements in vaccine development are helping researchers develop better vaccines against various diseases including human cytomegalovirus (HCMV). This is likely to boost the market for HCMB envelope glycoprotein B over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Cytomegalovirus Envelope Glycoprotein B Market Research Report
By Type
CSJ-148, CyMVectin, TRL-345, PPCM, Cytomegalovirus Vaccine, Others
By Application
Infectious Disease, Oncology, Women's Health, Others
By Companies
Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc, Vical Incorporated
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Human Cytomegalovirus Envelope Glycoprotein B Market Report Segments:
The global Human Cytomegalovirus Envelope Glycoprotein B market is segmented on the basis of:
Types
CSJ-148, CyMVectin, TRL-345, PPCM, Cytomegalovirus Vaccine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Disease, Oncology, Women's Health, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma Inc.
- Trellis Bioscience, Inc.
- Vakzine Projekt Management GmbH
- VBI Vaccine Inc
- Vical Incorporated
Highlights of The Human Cytomegalovirus Envelope Glycoprotein B Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CSJ-148
- CyMVectin
- TRL-345
- PPCM
- Cytomegalovirus Vaccine
- Others
- By Application:
- Infectious Disease
- Oncology
- Women's Health
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Cytomegalovirus Envelope Glycoprotein B Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human cytomegalovirus envelope glycoprotein B is a protein that is found on the surface of the virus. This protein helps to attach the virus to cells and allows it to enter these cells.
Some of the key players operating in the human cytomegalovirus envelope glycoprotein b market are Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc, Vical Incorporated.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Cytomegalovirus Envelope Glycoprotein B Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Cytomegalovirus Envelope Glycoprotein B Market - Supply Chain
4.5. Global Human Cytomegalovirus Envelope Glycoprotein B Market Forecast
4.5.1. Human Cytomegalovirus Envelope Glycoprotein B Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Cytomegalovirus Envelope Glycoprotein B Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Cytomegalovirus Envelope Glycoprotein B Market Absolute $ Opportunity
5. Global Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
5.3.1. CSJ-148
5.3.2. CyMVectin
5.3.3. TRL-345
5.3.4. PPCM
5.3.5. Cytomegalovirus Vaccine
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
6.3.1. Infectious Disease
6.3.2. Oncology
6.3.3. Women's Health
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Cytomegalovirus Envelope Glycoprotein B Demand Share Forecast, 2019-2026
9. North America Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
9.4.1. Infectious Disease
9.4.2. Oncology
9.4.3. Women's Health
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
9.7.1. CSJ-148
9.7.2. CyMVectin
9.7.3. TRL-345
9.7.4. PPCM
9.7.5. Cytomegalovirus Vaccine
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Cytomegalovirus Envelope Glycoprotein B Demand Share Forecast, 2019-2026
10. Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
10.4.1. Infectious Disease
10.4.2. Oncology
10.4.3. Women's Health
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
10.7.1. CSJ-148
10.7.2. CyMVectin
10.7.3. TRL-345
10.7.4. PPCM
10.7.5. Cytomegalovirus Vaccine
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Cytomegalovirus Envelope Glycoprotein B Demand Share Forecast, 2019-2026
11. Europe Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
11.4.1. Infectious Disease
11.4.2. Oncology
11.4.3. Women's Health
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
11.7.1. CSJ-148
11.7.2. CyMVectin
11.7.3. TRL-345
11.7.4. PPCM
11.7.5. Cytomegalovirus Vaccine
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Cytomegalovirus Envelope Glycoprotein B Demand Share, 2019-2026
12. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
12.4.1. Infectious Disease
12.4.2. Oncology
12.4.3. Women's Health
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
12.7.1. CSJ-148
12.7.2. CyMVectin
12.7.3. TRL-345
12.7.4. PPCM
12.7.5. Cytomegalovirus Vaccine
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Demand Share, 2019-2026
13. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Application
13.4.1. Infectious Disease
13.4.2. Oncology
13.4.3. Women's Health
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size and Volume Forecast by Type
13.7.1. CSJ-148
13.7.2. CyMVectin
13.7.3. TRL-345
13.7.4. PPCM
13.7.5. Cytomegalovirus Vaccine
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Cytomegalovirus Envelope Glycoprotein B Market: Market Share Analysis
14.2. Human Cytomegalovirus Envelope Glycoprotein B Distributors and Customers
14.3. Human Cytomegalovirus Envelope Glycoprotein B Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharma Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Trellis Bioscience, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Vakzine Projekt Management GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. VBI Vaccine Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Vical Incorporated
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook